comparemela.com

Latest Breaking News On - Rapport therapeutics - Page 4 : comparemela.com

Moderna s CFO on the $25 billion innovation plan to work past the post-COVID slump

New startup Arialys takes aim at the immune system, hoping to create neuropsychiatry drugs

Rapport Nabs Back-to-Back Funding Rounds - San Diego Business Journal

Rapport Nabs Back-to-Back Funding Rounds - San Diego Business Journal
sdbj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sdbj.com Daily Mail and Mail on Sunday newspapers.

Twice Rejected Diabetes Drug/Device Product Gets New Chance at Startup i2O

Intarcia Therapeutics’ GLP-1 agonist product candidate for type 2 diabetes now belongs to i2O Therapeutics, which will make the treatment’s case for approval at an upcoming FDA advisory committee meeting. The startup’s $46 million Series A financing is one of several recently announced funding rounds.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.